Erik Tambuyzer

Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively inhibit HDAC6. Augustine’s HDAC6 inhibitors have been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including neurodegenerative and cardio-metabolic diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium. ——— *Disclaimer* ——— We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, neurodegenerative and cardio-metabolic diseases through its next-generation approach to selectively inhibit HDAC6. Augustine’s HDAC6 inhibitors have been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions. Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including neurodegenerative and cardio-metabolic diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium. ——— *Disclaimer* ——— We wish to caution jobseekers that Augustine Therapeutics, only recruits for the positions that are posted on the company’s webpage and via the channels mentioned there. It will also not charge fees of any kind from candidates during the recruitment process. Any person or organization dealing with unauthorized parties is doing so at their own risk.

BioPontis Alliance for Rare Diseases is a non-profit corporation dedicated to the development of new therapeutic agents to treat rare diseases. The niche philanthropy uses a collaborative approach, partnering with patient organizations and academic researchers. BioPontis provides the plans and executes the preclinical translational scientific, early clinical development, patenting, and business relationship management. We bring the expertise that is needed to advance ideas for treatments into drug compounds that are ready for uptake by the biopharmaceutical and biotech industry. BioPontis Alliance for Rare Diseases is a global non-profit development hub, inviting corporate, private and foundation philanthropic support to address a global community of people affected with rare diseases whose health needs are too often neglected as ‘too rare to care.’

The Royal Flemish Academy of Belgium for Science and the Arts (KVAB) is an independent multidisciplinary society. Its membership, nominated and elected by peers, consists of professors, influential business leaders, artists and art experts. Together they aim to contribute to the promotion of science and art. The members of the Academy are divided into four divisions: natural sciences, humanities, arts and engineering sciences. These ‘Classes’, both independently and together, strive to contribute to a number of topics and developments that affect society in short and long term. As a result of their efforts, they formulate recommendations to the government, industry, education and research. They aim to be a valuable addition to the societal debate.